Physician profile
Daniel Levy
NPI 1306067814
$540,525.79
in general payments reported to CMS, 2019-2025
16 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $41K · 2021: $99K · 2022: $186K · 2023: $61K · 2024: $53K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138K · Travel and Lodging: $7,090 · Food and Beverage: $4,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,635.85 |
| Travel and Lodging | $7,090.08 |
| Food and Beverage | $4,587.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $391,135.93 | 2019-2023 | |
| Abbvie INC. | $148,110.75 | 2020-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $437.99 | 2020-2022 | |
| Revance Therapeutics, INC. | $335.67 | 2024-2025 | Daxxify, Daxi |
| Smith+Nephew, INC. | $138.83 | 2024-2025 | Grafix Pl |
| Dermavant Sciences, INC. | $90.39 | 2022-2023 | Vtama |
| Lilly USA, LLC | $59.49 | 2019-2024 | Zepbound, Jardiance |
| Janssen Biotech, INC. | $49.91 | 2019-2024 | Tremfya |
| Ucb, INC. | $33.74 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $31.56 | 2021-2024 | Aklief |
| Sientra, INC. | $23.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.85 | 2024 | |
| Amgen INC. | $20.46 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $18.86 | 2019 | |
| Organon LLC | $8.74 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Next Science LLC | $8.26 | 2023 | Xperience, Surgx, Blastx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.